ovcar3

UNC0379 is a selective, substrate-competitive inhibitor of the lysine methyltransferase (SETD8).

PROTAC CDK2 Degrader-1 (Compound 41) is a PROTAC degrader targeting cyclin-dependent kinase 2 (CDK2). It inhibits the phosphorylation of the RB protein in the CDK2-dependent cell line OVCAR3, with an IC50 ranging from 100-500 nM.

WEE1-IN-11 (Compound 13) serves as a potent CDK2 inhibitor with an IC50 of 2.0 nM. It exhibits inhibitory effects on several cell lines, including NCI-H446, A427, OVCAR3, C33A, and WiDr, with respective IC50 values of 93.9, 34.5, 86.7, 23.1, and 85 nM.

PKMYT1-IN-8 (Compound 137) is an inhibitor of PKMYT1, with an IC50 value of 9 nM. It also inhibits EPHB3, EPHA1, KIT, EPHB1, EPHA2, EPHA3, and EPHB2, exhibiting IC50 values of 1.79, 3.17, 4.29, 6.32, 6.83, 8.10, and 10.9 μM, respectively. Additionally, PKMYT1-IN-8 suppresses the proliferation of cancer cells OVCAR3 with a GI50 of 2.02 μM.

QR-6401, a selective macrocyclic CDK2 inhibitor, is orally active with IC50 values of 0.37 nM for CDK2 E1, 10 nM for CDK9 T1, 22 nM for CDK1 A2, 34 nM for CDK6 D3, and 45 nM for CDK4 D1. It exhibits potent antitumor activity in the OVCAR3 ovarian cancer xenograft model, indicating its potential for use in cancer research [1].

CDK2-IN-19 (Compound 32) is a selective, orally active CDK2 inhibitor (K i: 0.18 nM) that demonstrates anticancer activity in mice with OVCAR3 tumors [1].

Menominin A is a cyclic peptide discovered in the freshwater sponge-associated cyanobacterium Nostoc sp., exhibiting cytotoxic properties. It shows anti-proliferative activity against the ovarian cancer cell line OVCAR3, with an IC50 value of 3.1 μM. Menominin A holds potential for research in the field of cancer therapy.

Menominin B is a cyclic peptide identified in freshwater sponge-associated cyanobacteria Nostoc sp., known for its cytotoxic properties. It exhibits antiproliferative activity against the ovarian cancer cell line OVCAR3, with an IC50 of 2.4 μM. Menominin B holds potential for research in the field of anticancer therapies.